You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Novel Small Molecule Therapeutics for Pancreatic Cancer

    SBC: ChemRegen Inc            Topic: NCI

    Project Summary/Abstract Developing new ways to treat pancreatic cancer is a significant challenge. Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and results in an estimated 37,000 deaths/year. Pancreatic cancer therapeutic options are limited to surgery and/or combinations of chemotherapy and radiation. Unfortunately, late-stage diagnosis of pancreat ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. An innovative in situ cell reprogramming technology for cancer treatment

    SBC: QURGEN, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We invented an innovative protein induced Pluripotent Stem Cells (piPSCs) technology that generates piPSCs from normal fibroblast and cancer cells within 1-week with 90 4% conversion efficiency. Such high conversion efficiency enables us to pioneer an in situ cell reprogramming technology within the cancers of cancer-bearing animals. Instead of generating iPSCs ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Accurate Prostate Cancer Diagnosis for Active Surveillance Patients Using a Novel

    SBC: ProDevice Medical Supplies and Equipment LLC            Topic: NCI

    Project Abstract Active surveillance (AS) is becoming more accepted as a reasonable treatment option for men with low-risk prostate cancer (i.e. Gleason score 6, clinical stage T2a, PSA lt 10). Many AS protocols at major institutions call for a prostate saturation biopsy after initial diagnosis to confirm that the patient has no areas of higher-risk prostate cancer. For most patients who underwent ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. ChemoFilter: A Novel Catheter Device to Enable High-Dose Chemotherapy Treatment

    SBC: CHEMOFILTER, INC.            Topic: NCI

    Project Summary: Intravenous dosing of drugs for applications ranging from cancer chemotherapy to anti-microbials to lytic (blood clot dissolving) agents is limited by systemic toxicity. Currently, the only ways to remove drugs from the blood are throughnatural metabolism or costly impractical measures such as dialysis. Despite intense focus on targeted drug delivery agents, these therapies are c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema

    SBC: ADEPTHERA, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Destruction of lymphatic vessels during the treatment of breast cancer by surgery and/or radiation therapy can lead to the development of secondary lymphedema. The breast-cancer-related lymphedema is associated with debilitating limb swelling, chronic inflammation, tissue fibrosis, and increased susceptibility to infection. It has been estimated that approximat ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Intra-procedure Deformable Ultrasound-MRI Fusion for Prostate Biopsies

    SBC: ZMK Medical Technologies, Inc.            Topic: NCI

    This proposal is a collaborative effort between Yale University and the medical device company Eigen to develop a more robust and accurate method for the deformable fusion of pre-operative magnetic resonance images (MRI) and intra-procedure trans-rectal ultrasound (TRUS) images to guide prostate biopsy. Prostate cancer is a major cause of death in the U.S. and biopsy is the gold-standard for its d ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Validation of a Novel Treatment for Glioblastoma

    SBC: CURTANA PHARMACEUTICALS, INC.            Topic: NCI

    ? DESCRIPTION (provided by applicant): The goal of this application is to study in vivo efficacy of CT102, a newly discovered inhibitor of the OLIG2 transcription factor in animal models of glioblastoma (GBM), a highly underserved area of pharmacotherapy. In this proposal, the experienced drug discovery group at Curtana Pharmaceuticals Inc. will conduct a pre-clinical evaluation of selectivity ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting of Myc-Max dimerization for the treatment of cancer

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Myc is a key transcriptional regulator due to its critical role in many fundamental cellular processes, such as cell cycle progression and cell growth. Therefore, dysregulation of Myc expression can lead to disease, including cancer. Myc is overexpressed in many human tumors, and it is estimated that 1 in 7 cancer deaths in the United States are resultant of hi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Identification and Quantification of Sequence Specific RNA Modifications via the Alpha-Hemolysin Latch Zone

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): During this STTR program, Electronic BioSciences (EBS) proposes to develop a nanopore based system around our University of Utah collaborators newly developed technology that will be capable of identifying and quantifying sequence specific RNA modifications. A system capable of quantitative, low cost, high throughput, RNA modification characterization has the c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Removal of Amyloid-beta Peptides from the Alzheimer's Brain

    SBC: WE BIOSCIENCES, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): As the Alzheimer's disease (AD) population is growing rapidly, currently there are no cure treatments. The goal of this resubmitted STTR proposal is to conduct a preclinical study with pramlintide to prove a potential treatment for AD. We have revised the proposal significantly according to the reviewers' comments. Pramlintide is an FDA approved drug ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government